# OnCo record nct04274426 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct04274426/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct04274426", "NCT04274426" ;
  schema:name "Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer"@en ;
  schema:alternateName "MIROVA"@en ;
  schema:description "A phase 2 trial of Carboplatin, Doxorubicin, Pegylated liposomal doxorubicin, Gemcitabine and Mirvetuximab soravtansine in ovarian cancer, run by AGO Research GmbH, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct04274426/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04274426> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2021-10-13" ;
  onco:cancers <https://onco.cc/cancers/ovarian/> ;
  onco:technologies <https://onco.cc/technologies/adc/> ;
  onco:drugs <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/pegylated-liposomal-doxorubicin/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/mirvetuximab-soravtansine/> ;
  onco:companies <https://onco.cc/companies/ago-study-group/> .